agilon health

Positives: exiting and re‑contracting underperforming markets, reducing Part D exposure (<15%), and focusing on higher‑quality payor terms all improve future unit economics. Negatives: a large 2023 buyback ($200 million) preceded operating losses and a 1‑for‑25 reverse split in March 2026, suggesting weak timing and limited margin of safety.

Stock‑based compensation and working‑capital swings have diluted per‑share cash economics. Until sustained free cash flow arrives, repurchases or step‑ups in growth capex should be conservative.